New drug combination for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have been diagnosed with colorectal cancer that has spread (metastatic).
- You must have already tried at least one line of standard chemotherapy that included fluorouracil, oxaliplatin, and irinotecan, and your cancer either continued to grow or you couldn't tolerate the side effects.
- A recent scan (CT or MRI) must show a tumor that can be measured, and your overall health should be fairly good (able to do most daily tasks).
- Your kidney, liver, and blood cell counts need to be within certain limits, as checked by blood and urine tests.
- You must not have taken certain targeted cancer drugs (like fruquintinib, regorafenib, or anlotinib) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.